MUPIROCIN RESISTANCE IN STAPHYLOCOCCUS AUREUS IN A TERTIARY CARE HOSPITAL OF SOUTH INDIA â€“ A PROSPECTIVE STUDY
Objective: Mupirocin is a topical antibiotic used for the treatment of skin and soft tissue infections caused by Staphylococcus aureus and for the nasal decolonization of methicillin-resistant S. aureus (MRSA). The increasing reports of resistance to mupirocin are a matter of concern. We undertook this study to detect and differentiate the mupirocin resistance pattern and to analyze the susceptibility pattern among S. aureus isolates of our hospital.
Methods: This is a prospective laboratory-based study conducted during the period Mayâ€“September 2014. Clinical samples that grew S. aureus during the study period were tested for mupirocin resistance using the 5 Î¼g and 200 Î¼g discs. Minimum inhibitory concentration (MIC) detection of resistant strains was performed using the E-test.
Results: Mupirocin resistance was seen in 4.81% of our S. aureus isolates; all of which exhibited high-level resistance with MIC â‰¥1024 Î¼g/ml.
Conclusions: The resistance is bound to rise with the increased usage of mupirocin; regular testing will help in tackling this upcoming problem and in preserving this important antibiotic against MRSA.
2. Husean IY, Al-Rahman A, Al-Obaidi IR. Optimizing nasal formulation for prevention of serious infections caused. Int J Pharm Pharm Sci 2015;7:496-503.
3. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis 2009;49:935-41.
4. Rahman M, Noble WC, Cookson B. Mupirocin resistant Staphylococcus aureus. Lancet 1987;2:387.
5. Watanabe H, Masaki H, Asoh N, Watanabe K, Oishi K, Kobayashi S, et al. Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2001;39:3775-7.
6. Farmer TH, Gilbart J, Elson SW. Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus. J Antimicrob Chemother 1992;30:587-96.
7. Casewell MW, Hill RL. In-vitro activity of mupirocin (â€œpseudomonic acidâ€) against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1985;15:523-31.
8. Gilbart J, Perry CR, Slocombe B. High-level mupirocin resistance in Staphylococcus aureus: Evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother 1993;37:32-8.
9. Seah C, Alexander DC, Louie L, Simor A, Low DE, Longtin J et al. Mup B, a new high level mupirocin resistance mechanism in Staphylococcus aureus. Antimicrob Agents Chemother 2012;56:1916 20.
10. De Oliveira NE, Cardozo AP, Marques Ede A, dos Santos KR, Giambiagi deMarval M. Interpretive criteria to differentiate low and high level mupirocin resistance in Staphylococcus aureus. J Med Microbiol 2007;56:937 9.
11. Hudson IR. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: A review of recent experience. J Hosp Infect 1994;27:81-98.
12. SareyyÃ¼poÄŸlu B, Ozyurt M, HaznedaroÄŸlu T, ArdiÃ§ N. Detection of methicillin and mupirocin resistance in staphylococcal hospital isolates with a touchdown multiplex polymerase chain reaction. Folia Microbiol (Praha) 2008;53:363-7.
13. Orrett FA. The emergence of mupirocin resistance among clinical isolates of methicillin resistant Staphylococcus aureus in Trinidad: A first report. Jpn J Infect Dis 2008;61:107 10.
14. Jones JC, Rogers TJ, Brookmeyer P, Dunne WM Jr., Storch GA, Coopersmith CM, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007;45:541-7.
15. Daskalaki M, Otero JR, Chaves F. Molecular characterization of resistance to mupirocin in methicillin resistant Staphylococcus aureus isolates in a tertiary hospital in Spain. J Antimicrob Chemother 2009;63:826 8.
16. Liu QZ, Wu Q, Zhang YB, Liu MN, Hu FP, Xu XG, et al. Prevalence of clinical meticillin resistant Staphylococcus aureus [MRSA] with high level mupirocin resistance in Shanghai and Wenzhou, China. Int J Antimicrob Agents 2010;35:114 8.
17. Yun HJ, Lee SW, Yoon GM, Kim SY, Choi S, Lee YS, et al. Prevalence and âˆžmechanisms of low and high level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 2003;51:619 23.
18. Performance Standards for Antimicrobial Susceptibility Testing; 24th Informational Supplement, Clinical and Laboratory Standards Institute [CLSI] M100-S20. Vol. 30, No.1. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
19. Oommen SK, Appalaraju B, Jinsha K. Mupirocin resistance in clinical isolates of staphylococci in a tertiary care centre in South India. Indian J Med Microbiol 2010;28:372-5.
20. Gadepalli R, Dhawan B, Mohanty S, Kapil A, Das BK, Chaudhry R, et al. Mupirocin resistance in Staphylococcus aureus in an Indian hospital. Diagn Microbiol Infect Dis 2007;58:125-7.
21. Jayakumar S, Meerabai M, Banu SS, Mathew R, Kalyani M, Lal Y B. Prevalence of high and low level mupirocin resistance among staphylococcal isolates from skin infection in a tertiary care hospital. J Clin Diagn Res 2013;7:238 42.
22. Rajkumari N, Mathur P, Bhardwaj N, Gupta G, Dahiya R, Behera B, et al. Resistance pattern of mupirocin in methicillinresistant Staphylococcus aureus in trauma patients and comparison between disc diffusion and E-test for better detection of resistance in low resource countries. J Lab Phys 2014;6:91-5.
23. Kaur DC, Narayan PA. Mupirocin resistance in nasal carriage of Staphylococcus aureus among healthcare workers of a tertiary care rural hospital. Indian J Crit Care Med 2014;18:716-21.
24. Chaturvedi P, Singh AK, Singh AK, Shukla S, Agarwal L. Prevalence of mupirocin resistant Staphylococcus aureus isolates among patients admitted to a tertiary care hospital. N Am J Med Sci 2014;6:403-7.
25. Kim MN, Kim H, An D, Ji M, Lee M, Kim AR, et al. Mupirocin resistance among MRSA surveillance isolates from neonatal intensive care unit under 10 year search and destroy policy compared to. BMC Proc 2011;5 Suppl 6:171.
26. McNeil JC, Hulten KG, Kaplan SL, Mason EO. Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children. Antimicrob Agents Chemother 2011;55:2431-3.
27. Hurdle JG, Oâ€™Neill AJ, Mody L, Chopra I, Bradley SF. In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J Antimicrob Chemother 2005;56:1166-8.
28. Satyam SM, Bairy KL, Pirasanthan R, Vishnav RL, Kashyap S. Influence of topical retapamulin (1%) ointment, sofinox- Rd cream, sofinox cream (2%), zinc fusidate cream (2%) and zinc fusidate ointment (2%) on nasal mucosal surface safety in New Zealand albino rabbits. Int J Pharm Pharm Sci 2015;7:183-6.
29. McConeghy KW, Mikolich DJ, LaPlante KL. Agents for the decolonization of methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2009;29:263-80.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.